1. Name and Nature of the Subject Matter (For preferred shares, the agreed issuance conditions such as dividend rate should also be specified): Achi Capital Partners Global Fund II LP 2. Date of Occurrence of Fact: 2026/5/6~2026/5/6 3. Date of Board of Directors' Resolution: May 6, 2026 (ROC year 115) 4. Other Resolution Dates: Not applicable 5. Quantity of Transaction, Price per Unit, and Total Transaction Amount: No transaction quantity, no unit price. Total transaction amount: US$21,000 thousand 6. Counterparty and its Relationship with the Company (If the counterparty is a natural person and not a related party of the company, their name may be omitted): Counterparty: Achi Capital Partners Global Fund II LP; Non-related party 7. If the counterparty is a related party, the reasons for selecting the related party as the transaction object, the previous transferor, the relationship between the previous transferor and the company and the counterparty, the previous transfer date, and transfer amount shall also be announced: Not applicable 8. If the owner of the transaction object within the past five years was a related party of the company, the date and price of acquisition and disposal by the related party and its relationship with the company at the time of the transaction shall also be announced: Not applicable 9. Relevant matters concerning the disposal of claims (including the type of collateral attached to the claims, if the claims are against a related party, the name of the related party and the book value of the claims against that related party shall also be announced): Not applicable 10. Disposal Profit (or Loss) (Not applicable to acquisition of securities) (For deferred items, explain the recognition status in a table): Not applicable 11. Delivery or Payment Terms (including payment period and amount), Contractual Restrictions, and Other Important Agreements: According to contract terms 12. Method of Determining this Transaction, Reference Basis for Price Determination, and Decision-making Unit: Method of determining the transaction, basis for price determination: According to contract terms; Decision-making unit: Board of Directors 13. Net value per share of the acquired or disposed securities target company: Not applicable 14. As of now, the accumulated quantity, amount, shareholding ratio, and restrictions on rights (e.g., pledge status) of the securities in this transaction (including this transaction): No transaction quantity; Amount: US$21,000 thousand; Shareholding ratio approximately 3%; Restrictions on rights: None 15. As of now, the investment in securities (including this transaction) listed in Article 3 of the 'Regulations Governing the Acquisition and Disposal of Assets by Public Companies' as a percentage of the company's total assets and equity attributable to owners of the parent in the most recent financial report, and the working capital amount in the most recent financial report (Note 2): Ratio to total assets: 17.76%; Ratio to owners' equity: 23.19%; Working capital: NT$595,241 thousand 16. Broker and Brokerage Fees: Not applicable 17. Specific Purpose or Use of Acquisition or Disposal: Financial investment 18. Opinions of Dissenting Directors in this Transaction: None 19. Is this Transaction a Related Party Transaction: No 20. Date of Supervisor's Approval or Audit Committee's Consent: May 6, 2026 (ROC year 115) 21. Did the CPA issue an unqualified opinion on this transaction: Not applicable 22. Name of Accounting Firm: Not applicable 23. Name of CPA: Not applicable 24. CPA's Certificate Number: Not applicable 25. Does it involve a change in operating model: No 26. Explanation of change in operating model: Not applicable 27. Transaction status with counterparty in the past year and estimated in the next year: None 28. Source of Funds: Own funds 29. Date of Previous Material Information Announcement on the Same Event: Not applicable 30. Other Matters to be Specified: None

FACT BOX

  • Source: PR Times
  • Category: Funding
  • Organizations: Achi Capital Partners Global Fund II LP
  • Dates in source: 115/5/6